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STUDYQUESTION:Does ﬁrst-line chemotherapy affect the quality of ovarian pre-antral follicles and stromal tissue in a population of young
patients?
SUMMARY ANSWER: Exposure to ﬁrst-line chemotherapy signiﬁcantly impacts follicle viability, size of residual intact follicles, steroid
secretion in culture and quality of the stromal compartment.
WHAT IS KNOWNALREADY: First-line chemotherapy is considered to have a low gonadotoxic potential, and as such, does not represent
an indication for fertility preservation. Studies investigating the effects of chemotherapy on the quality of ovarian tissue stored for fertility
preservation in young patients are limited and the results sometimes contradictory.
STUDY DESIGN, SIZE, DURATION: We conducted a retrospective cohort study including young patients referred to three centers
(Helsinki, Oslo and Tampere) to perform ovarian tissue cryopreservation for fertility preservation between 2003 and 2018.
PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 43 patients (age 1–24 years) were included in the study. A total of
25 were exposed to ﬁrst-line chemotherapy before cryopreservation, whereas 18 patients were not. Density and size of follicles divided by
developmental stages, prevalence of atretic follicles, health of the stromal compartment and functionality of the tissue in culture were evaluated
and related to age and chemotherapy exposure. Activation of dormant follicles and DNA damage were also assessed.
MAIN RESULTS AND THE ROLE OF CHANCE: Patients exposed to ﬁrst-line chemotherapy showed a signiﬁcantly higher density of
atretic primordial and intermediary follicles than untreated patients. The intact primordial and intermediary follicles were signiﬁcantly smaller
in size in patients exposed to chemotherapy. Production of steroids in culture was also signiﬁcantly impaired and a higher content of collagen
and DNA damage was observed in the stromal compartment of treated patients. Collectively, these observations may indicate reduced quality
and developmental capacity of follicles as a consequence of ﬁrst-line chemotherapy exposure. Neither increased activation of dormant follicles
nor elevated levels of DNA damage in oocyte nuclei were found in patients exposed to chemotherapy.
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LIMITATIONS, REASONS FOR CAUTION: The two groups were not homogeneous in terms of age and the patients were exposed
to different treatments, which did not allow us to distinguish the effect of speciﬁc agents. The limited material availability did not allow us to
perform all the analyses on the entire set of patients.
WIDER IMPLICATION OF THE FINDINGS: This study provides for the ﬁrst time a comprehensive analysis of the effects of ﬁrst-line
chemotherapy on the health, density and functionality of follicles categorized according to the developmental stage in patients under 24 years
of age. When exposed to these treatments, patients were considered at low/medium risk of infertility. Our data suggest a profound impact
of these relatively safe therapies on ovarian health and encourages further exploration of this effect in follow-up studies in order to optimize
fertility preservation for young cancer patients.
STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Swedish Childhood Cancer Foundation, the Finnish
Cancer Society, the Finnish Pediatric Research Foundation, the Väre Foundation for Pediatric Cancer Research, The Swedish Research Council,
the Stockholm County Council (ALF project) and Karolinska Institutet. The authors have no conﬂict of interest to declare.
Key words: childhood cancer / chemotherapy / fertility preservation / follicle quality / DNA damage
Introduction
Premature ovarian insufficiency (POI) and infertility are common
adverse effects of cancer treatment. Even when ovarian function is
maintained, cancer survivors have a lower chance to achieve pregnancy
than expected (Anderson et al., 2018; van Dorp et al., 2018). The toxic
potential of chemo- and radiotherapy varies based on the agent’s type
and dose (Meirow and Nugent, 2001; Lee et al., 2006). Alkylating
agents and radiation to the ovarian ﬁeld are associated with the highest
risk of infertility (Wallace et al., 2003; Donnez and Dolmans, 2014).
Cryopreservation of mature oocytes or embryos are established
clinical procedures to preserve fertility in adult patients undergoing
cancer treatments (Oktay et al., 2018). For women who cannot post-
pone the start of treatment, ovarian tissue cryopreservation (OTC)
is the only remaining option. Post-pubertal, cryopreserved tissue re-
transplanted to the patient can restore ovarian function and fertility,
with more than 130 live births reported worldwide (Donnez and
Dolmans, 2017). OTC is the only feasible approach for fertility preser-
vation in pre-pubertal girls, for whom retrieval of mature oocytes is
not an option (Jadoul et al., 2010; Wallace et al., 2016; Donnez and
Dolmans, 2017; Oktay et al., 2018). This approach is, however, still
considered experimental. Ovarian tissue stored from pediatric patients
has been successfully used for induction of puberty (Poirot et al.,
2012; Ernst et al., 2013). Recently, two reports describe successful
pregnancies stemming from transplantation of ovarian tissue collected
when the patients were 13 (Demeestere et al., 2015) and 9 years old
(Matthews et al., 2018).
The major centers routinely carrying out OTC offer the procedure
when the estimated risk of developing POI is greater than 50%,
based on the type of disease and treatment (Donnez et al., 2013;
Wallace et al., 2016; Donnez and Dolmans, 2017; Jensen et al., 2017).
At diagnosis, most girls are at low/medium risk of infertility and
cryopreservation will not be offered. However, some patients will fall
in the high-risk category later on due to poor treatment response or
disease relapse and will hence be offered OTC after the initiation of
treatments (Wallace et al., 2014).
A limited number of reports describe the effects of chemotherapy
on ovarian follicles in pediatric populations (Marcello et al., 1990; Famil-
iari et al., 1993; Abir et al., 2008; Fabbri et al., 2012; Asadi Azarbaijani
et al., 2015; Duncan et al., 2015; El Issaoui et al., 2016). A normal
density of viable pre-antral follicles has been observed in patients
exposed to chemotherapy, compared to non-exposed ones, especially
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at younger ages (Abir et al., 2008; Fabbri et al., 2012; El Issaoui et al.,
2016). However, Abir et al. (2008, 2016) reported a deterioration in
follicular ultrastructure in patients exposed to chemotherapy before
OTC. We have previously described decreased in vitro survival and
maturation of ovarian follicles from cancer patients aged 1–35 years
exposed to chemotherapy (Asadi Azarbaijani et al., 2015).
In the present study, we further characterized the effects of exposure
to ﬁrst-line chemotherapy on pre-antral follicles and ovarian stroma in
a cohort of girls and young women with cancer.
Materials and Methods
Study population
A total of 43 young patients who underwent fertility preservation
between 2003 and 2018 were included. The hospital, age, diagnosis,
treatment and cumulative doses of alkylating agents and anthracyclines
[cyclophosphamide equivalent doses (CEDs; Green et al., 2014) and
isotoxic dose equivalents (DIE), respectively (Shankar et al., 2008)
(Supplementary Materials and Methods)] are listed in Table I. Table I
further indicates the use of samples in the different assays. As the
material is very limited and precious, we could not carry out every
analysis in all samples. Altogether, 27 of the samples in this study were
from the same cohort used in our previous work (Asadi Azarbaijani
et al., 2015).
Ethical approval
Ovarian tissue samples were donated by fertility preservation patients
treated at the Children’s Hospital of the University Central Hospital
of Helsinki (Finland), the Department of Gynecology of the University
Hospital of Tampere (Finland) and the Department of Gynecology of
the Oslo University Hospital (Norway). Adult patients from Tampere
andOslo were offeredOTC as a part of fertility preservation program,
and they signed an informed consent for quality control of ovarian tis-
sue including morphological analysis and in vitro culture. Requirements
for further ethical licenses were discussed with Oslo University Hos-
pital, Finnish National Supervisory Authority for Welfare and Health
and Finnish Medicines Agency. Since all patients had given their written
informed consent concerning the use of thematerial for scientiﬁc work,
no further ethical permits were required in accordance with the Medial
Research Act (488/1999) and Act on the Medical Use of Human
Organs, Tissues and Cells (101/2001).
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Table I Main clinical characteristics of the study population and type of assays performed for each patient.
Pt Site First-line
treatment
TFL Age Dx Assays
........................ ........ .......... .......... .................................................................................................
CED DIE days years Histology Steroid H2AX FOXO-3A Trichrome Tunel
..................................................................................................................................................................................
1 H 31560 300 7 12 ES 1 1 0 0 0 0
2 H 3600 210 11 5 ALL 1 1 0 0 1 0
3 H 2000 120 28 1 ALL 1 1 0 0 0 0
4 H 0 300 30 6 AML 1 1 0 0 1 1
5 H 0 320 44 4 AML 0 0 0 0 0 1
6 H 20840 225 55 1 NBL 1 1 0 0 1 0
7 H 11400 120 30 2 NBL 1 1 0 0 1 0
8 H 9496 260 9 15 ALL 1 1 0 0 0 0
9 H 6000 450 26 11 ALL 1 1 0 0 1 0
10 H 4100 180 18 15 NHL 1 1 0 0 0 0
11 H 2000 120 18 16 ALL 1 1 0 0 0 0
12 H 10248 90 17 5 RMS 1 1 1 0 0 0
13 O 8540 120 14 10 RMS 1 1 0 1 0 0
14 O 6200 300 35 20 NHL 1 1 1 1 1 1
15 O 4800 200 21 24 ALL 1 1 0 1 0 1
16 H 5589 135 55 3 NBL 0 0 1 0 0 0
17 H 23676 360 26 7 ES 0 0 1 0 0 0
18 H 7332 240 20 16 RMS 0 0 1 0 0 1
19 H 1272 0 8 2 PNET 0 0 1 0 0 0
20 H 5853 240 15 16 RMS 0 0 1 0 0 0
21 H 2100 0 48 4 NBL 0 0 1 0 0 0
22 H 5928 0 26 1 PNET 0 0 1 0 0 0
23 H 39593 360 30 11 RMS 0 0 1 0 0 0
24 H 4000 150 25 3 NBL 0 0 0 0 0 1
25 H 1900 60 11 10 WT 0 0 0 0 0 1
26 H 0 0 - 15 AA 1 1 1 0 0 1
27 O 0 0 - 12 ES 1 1 0 1 1 1
28 O 0 0 - 23 HL 1 1 0 0 1 0
29 O 0 0 - 20 NHL 1 1 0 0 1 0
30 O 0 0 - 16 OS 1 1 0 0 1 0
31 O 0 0 - 14 HL 1 1 1 1 1 0
32 O 0 0 - 24 ES 1 1 0 1 1 1
33 O 0 0 - 15 NBL 1 1 0 0 0 0
34 O 0 0 - 15 NHL 1 1 0 0 0 0
35 O 0 0 - 19 NHL 1 1 1 1 0 1
36 O 0 0 - 22 ALL 1 1 1 1 0 0
37 T 0 0 - 19 ALL 1 1 0 0 0 0
38 T 0 0 - 19 ALL 1 1 0 0 0 0
39 H 0 0 - 3 SCID 0 0 1 0 0 1
40 H 0 0 - 7 AA 0 0 1 0 0 0
41 H 0 0 - 8 CML 0 0 1 0 0 0
42 H 0 0 - 20 PNET 0 0 1 0 0 0
43 H 0 0 - 2 WT 0 0 0 0 0 1
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute mieloid leukemia; CED, cyclophosphamide equivalent doses (mg/m2); CML, chronic myeloid leukemia; DIE,
doxorubicin isotoxic equivalent (mg/m2); Dx, diagnosis; ES, Ewing sarcoma; H, Helsinki; HL, Hodgkin lymphoma; NBL, neuroblastoma; NHL, non-Hodgkin lymphoma; O, Oslo;
OS, osteosarcoma; PNET, primitive neuroectodermal tumour; Pt, patient; RMS, rhabdomyosarcoma; SCID, severe combined immunodeﬁciency; T, Tampere; TFL, time from last
chemotherapy dose before ovarian tissue cryopreservation; WT, Wilms tumor. 0 = assay not performed; 1 = assay performed.
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Pediatric patients were included from Children’s Hospital in Helsinki
where they participated in a fertility preservation research project
approved by the Ethics Committee of Helsinki University Central
Hospital (license number 340/13/03/03/2015). Written informed
consents for pediatric patients were given by their guardians and by
all age-appropriate patients..
Ovarian tissue handling
Ovarian cortical tissue was collected from a total of 43 patients
(Table I). For 27 patients, tissue was ﬁxed in formalin prior to cryop-
reservation and used for immunohistochemical processing. For 11 of
these patients and 16 others (total 27 patients), frozen thawed ovarian
tissue (ca 2× 3× 1.5 mm3) was ﬁxed in Bouin’s solution and used for
morphometric evaluation as described earlier (Asadi Azarbaijani et al.,
2015).
Morphometric analysis
Two blinded observers evaluated a subset of 10 sections independently
and the results showed an inter-observer concordance above 90%.
Following this, each observer evaluated half of the study material.
Hematoxylin–eosin stained sections were digitalized using a spectral
scanner (Vectra 3 system, Perkin Elmer, MA, USA) and every ﬁfth
section was evaluated using PannoramicViewer software (3DHistech,
Budapest, Hungary). In order to avoid double counting, only follicles
with a clear oocyte nucleus were counted and classiﬁed according
to previously established morphological criteria (Gougeon, 1996): (i)
primordial follicles, oocyte surrounded by a single layer of ﬂattened
granulosa cells; (ii) intermediary follicles, oocyte surrounded by a
single layer of ﬂattened and at least two cuboidal granulosa cells; (iii)
primary follicles, oocyte surrounded by one complete layer of cuboidal
granulosa cells; and (iv) secondary follicles, oocyte surrounded by
more than one layer of cuboidal granulosa cells. Follicle health was
assessed based on follicle shape, oocyte nucleus, oocyte cytoplasm and
granulosa cells. In particular, a follicle was considered intact if the round
shape was preserved, there was no contraction of the cytoplasm, the
oocyte nucleus was centrally located, round and not pyknotic, if there
was full contact between the oocyte and the surrounding granulosa
cells and no eosinophilia of the cytoplasm. Atretic follicles were those
with a distorted follicle shape, dislocated or detached granulosa cells,
non-circular or pyknotic oocyte nucleus or eosinophilic cytoplasm
(Supplementary Fig. S1).
Mean follicle diameter and mean oocyte nucleus diameter was
recorded for each annotated follicle by taking two perpendicular mea-
surements using the follicle basement membrane or oocyte nuclear
membrane as a reference. The arithmetic mean of the two measure-
ments was used for ﬁnal calculations..
Staining of ovarian tissue sections
Fork head box O3A (FOXO3A) analysis was performed in one section
‘per’ patient in 8 patients (3 treated and 5 untreated) and gammaH2AX
(H2A histone family member X phosphorylated on serine 139) analysis
in one section ‘per’ patient in 18 patients (8 untreated and 10 treated).
In brief, following antigen retrieval, slides were blocked in 5% BSA and
normal donkey serum (S30, EMDMillipore, Darmstadt, Germany) and
then incubated in polyclonal rabbit FOXO3A antibody (PA5-27145,
Thermo Fisher Scientiﬁc, MA, USA), polyclonal rabbit gammaH2AX
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antibody (ab2893, Abcam, Cambridge, UK) or polyclonal rabbit IgG
antibody (ABIN376827, antibodies-online, Aachen, Germany) as neg-
ative control overnight at 4◦C. Primary antibodies were detected using
donkey anti-rabbit Alexa Fluor 555 conjugated antibody (A31572,
LifeTech, MA, USA) for 1 h at room temperature. Sections were
mounted using VECTASHIELD mounting media with DAPI (H-1200,
VectorLabs, CA, USA).
For detection of ﬁbrotic areas in the ovarian stroma, trichrome stain-
ing was performed on samples ﬁxed in Bouin’s after thawing using tri-
chrome stain kit (ab150686, Abcam, Cambridge, UK) and one section
‘per’ patient in 12 patients (6 untreated and 6 treated patients). Brieﬂy,
tissue sections were incubated inWeigert’s iron hematoxylin for 5 min,
followed by Biebrich scarlet/acid fuchsin solution for 15 min, phos-
phomolybdic/phosphotungstic acid solution for 10 min, aniline blue
solution for 5 min and acetic acid solution for 3 min before dehydration
(95% ethanol and 100% ethanol) and clearing (xylene for 10 min). Tis-
sue sections were mounted using Pertex® (Histolab, Askim, Sweden).
For stromal cell death detection, TUNEL staining assay was carried
out (11684795910, Roche, Penzberg, Germany) using freshly formalin-
ﬁxed paraffin-embedded samples and one section ‘per’ patient in 13
patients (6 untreated and 7 treated). In brief, de-paraffinized and rehy-
drated tissue sections were treated with proteinase K and incubated
with TUNEL reaction mixture for 1 h at 37◦C. Positive controls were
treated with DNase I for 20 min at room temperature prior to TUNEL
reaction. Negative controls were incubated without detection enzyme.
Samples were mounted using VECTASHIELD Antifade Mounting
Medium with DAPI (Vector laboratories, Peterborought, UK).
Details of imaging of stained ovarian tissue sections are given in
Supplementary Materials and Methods.
Steroid production in culture
Follicle function was evaluated by measuring steroid hormones in used
culture media from ovarian tissue pieces thawed and cultured for
7 days as described earlier (Asadi Azarbaijani et al., 2015). Concentra-
tions of cortisol, corticosterone, estradiol, androstenedione, 17a-OH-
progesterone, dehydroepiandrosterone, dihydrotestosterone, testos-
terone and progesterone were quantiﬁed in media samples from 27
patients on Days 4 and 7 of culture, and in nine blank media samples
as controls, using an established ultra-performance liquid chromatog-
raphy tandem mass spectrometry method (Hao et al., 2018).
Statistical analyses
Statistical analyses were performed using the SigmaStat (v 11.00)
package (SPSS, Inc., IL, USA), R (R Core Team, 2018) and RStudio
program (RStudio Team, 2015) with the packages ggplot2 (Wickham,
2009), gplots (Warnes et al., 2016), reshape2 (Wickham, 2007) and
dichromat (Lumley, 2013). Mann–Whitney U test was used to com-
pare follicle densities, follicle and oocyte nucleus diameters, steroid
concentrations, ﬁbrotic areas, TUNEL signal and gammaH2AX foci
numbers between the treated and the untreated patient group. Results
are shown as medians and interquartile range. Outliers are deﬁned
as values that fall more than 1.5 times the interquartile range above
the third quartile or below the ﬁrst quartile and shown as dots in
the ﬁgures. All values were included in statistical analyses. Chi-Square
analysis was used to compare the proportions of different follicle
classes in treated and untreated patients. Morphometric analysis data
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were used to verify correlation between themorphological parameters
and age, CED, DIE and steroid concentrations using Spearman’s rank
correlation. Forward stepwise regression was used for the evaluation
of the major predictor when more than one variable correlated with
morphological parameters in Spearman’s analysis. Differences were
considered statistically signiﬁcant at P< 0.05.
Results
First-line chemotherapy affects follicle
density and size
Follicular density was evaluated in ovarian samples from 14 treated
and 13 untreated cancer patients (Fig. 1). A total of 3154 follicles
(2408 in the treated and 746 in the untreated group) were counted.
Representative histological images of ovarian tissue samples from both
patient groups are shown in Fig. 1. Themain clinical data are reported in
Table I. The treated patients had received a median cumulative dose of
6100 CED (0–20,840 mg/m2) and 205 DIE (90–450 mg/m2) and were
signiﬁcantly younger than the patients who were not treated (Table II).
The density of atretic primordial and intermediary follicles was higher
in treated patients compared to untreated ones (Table II; Fig. 2A).
Treated patients also had a signiﬁcantly lower density of intact primary
follicles compared to untreated patients. When the proportions of
follicles were compared instead of densities, treated patients were
found to have a signiﬁcantly higher proportion of atretic follicles in all
categories (Fig. 2B). The total follicle density did not differ between the
treated and the untreated group (Table II).
In treated patients, intact and atretic primordial follicle and oocyte
nucleus diameters were signiﬁcantly smaller compared to those of
untreated patients (Fig. 3; Table III). Intact intermediary follicles had
also a signiﬁcantly lower follicular diameter in treated patients.
CED was positively correlated with the total density of atretic
follicles (i.e. the sum of atretic primordial, intermediary and primary
follicles), atretic primordial follicles and atretic intermediary follicles
and was negatively correlated with the density of total and intact
primary follicles and with the diameter of intact intermediary follicles.
DIE was positively correlated with the density of atretic total follicles,
atretic primordial and atretic intermediary follicles and was negatively
correlated with the density of intact primary follicles. DIE showed
also a negative correlation with the follicular and nuclear diameter of
intact primordial follicles and with the diameter of intact intermediary
follicles. Age was inversely correlated with the density of atretic
primordial follicles (Supplementary Table S1). Forward stepwise
regression analysis showed that among age, CED and DIE, age was
the major determinant of atretic total follicle density (P=0.017),
atretic primordial follicle density (P=0.026), atretic intermediary
follicle density (P=0.010) and of the ratio between growing and total
follicles (P=0.024). The diameter of intact intermediary follicles and
the density of intact primary follicles were instead mainly inﬂuenced by
DIE (P=0.024 and P=0.023, respectively).
No increase in follicle activation in
chemotherapy exposed ovarian tissue
As a measure of follicle recruitment, i.e. activation of follicle growth,
the ratio of intact growing follicles to the total number of follicles
was compared between treated and untreated patients. The ratio was
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Figure 1 Representative images of ovarian tissue sections.
Hematoxylin–eosin stained ovarian tissue sections from four patients
treated with chemotherapy prior to OTC (Patient number 4, 2, 7, 6;
clockwise) and four untreated patients (Patient number 31, 34, 28, 29;
clockwise).
signiﬁcantly reduced in treated patients compared to untreated ones
(Fig. 4A), suggesting that there is no increase in the recruitment of
primordial follicles but rather a decrease in the number of growing
follicles, consistent with the lower density of intact primary follicles
observed in the treated group (Fig. 2A; Table II). We further stud-
ied follicle activation through FOXO3A immunostaining. Upon follicle
activation, transcription factor FOXO3A is relocated from the nucleus
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Table II Density of intact and atretic follicles (follicles/mm3) in cryopreserved human ovarian tissues from
cancer patients untreated and treated with chemotherapy before ovarian tissue cryopreservation.
Untreated (n=13) Treated (n=14) P
.................................................................................................................................................................
Age (y) mean± SD 17.9 ± 3.7 10.2 ± 7.2 0.007
CED (mg/m2) 0.0 (0.0) 6100(3200-10536) <0.001
DIE (mg/m2) 0.0 (0.0) 205 (120-300) <0.001
Total follicle density 421 (328-708) 764 (168-1,658) 0.452
Intact follicles 10.8 (0.0-231) 31.4 (0.0-154) 0.243
Atretic follicles 76.1 (34.4-332) 506 (81.6-1,488) 0.027
Primordial follicle density 142 (72.1-268) 225 (37.6-850) 0.593
Intact primordial follicles 105 (52.3-259) 73.0 (19.4-315) 0.511
Atretic primordial follicles 20.7 (0.0-34.5) 116 (13.4-621) 0.054
Intermediary follicle density 181 (156-462) 410 (137-736) 0.452
Intact intermediary follicles 136 (74.8-271) 82.9 (0.0-169) 0.138
Atretic intermediary follicles 49.2 (9.4-183) 308 (41.9-711) 0.041
Primary follicle density 22.6 (19.5-43.4) 3.3 (0.0-24.3) 0.028
Intact Primary follicles 20.6 (0.0-30.4) 0.0 (0.0) 0.005
Atretic Primary follicles 0.0 (0.0-21.2) 0.0 (0.0-22.3) 0.935
Data are expressed as median (quartiles), except for age that is expressed as mean (standard deviations). Comparison between untreated and treated subjects
are reported. Bold characters emphasize signiﬁcant P-values.
Figure 2 Follicle density is impacted by ﬁrst-line chemotherapy. (A) Follicle densities of intact and atretic follicles at different stages of
development (primordial, intermediary and primary). Atretic intermediary follicles were found to be increased in treated patients, while intact primary
follicle density was decreased ∗(P< 0.05). (B) Percentage of intact/atretic follicles of 14 treated and 13 untreated patients. A signiﬁcantly higher
percentage of atretic follicles of all developmental stages was observed in treated patients ∗∗∗(P< 0.001).
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Figure 3 Size of follicle and oocyte nucleus is decreased by ﬁrst-line chemotherapy.Box plots representing diameters of different stages
of follicles and their oocyte nuclei of treated (n=14; black bars) and untreated (n=13; white bars) patients. Intact and atretic primordial follicles and
their oocyte nuclei as well as intact intermediary follicles were signiﬁcantly smaller in treated patients ∗(P< 0.05), while no difference in primary follicle
and oocyte nucleus diameters was observed.
Table III Follicle and oocyte nucleus diameters (μm) of intact and atretic follicles in cryopreserved human
ovarian tissues from cancer patients untreated and treated with chemotherapy before ovarian tissue
cryopreservation (OTC).
Untreated (n=13) Treated (n=14) P
.................................................................................................................................................................
Intact primordial follicles
Follicle diameter 38.7 (35.1-40.0) 33.4 (31.2-36.4) 0.042
Nuclear diameter 16.8 (14.8-17.3) 15.1 (13.8-15.8) 0.042
Atretic primordial follicles
Follicle diameter 36.6 (31.3-40.6) 26.9 (23.9-31.5) 0.017
Nuclear diameter 14.4 (12.3-15.9) 11.2 (9.6-13.1) 0.043
Intact intermediary follicles
Follicle diameter 39.6 (36.8-43.1) 35.3 (32.1-38.7) 0.009
Nuclear diameter 15.9 (14.8-17.1) 14.1 (13.3-15.3) 0.081
Atretic intermediary follicles
Follicle diameter 34.0 (27.5-36.7) 31.5 (27.1-33.2) 0.336
Nuclear diameter 11.9 (10.6-14.1) 11.8 (9.9-14.0) 0.780
Intact primary follicles
Follicle diameter 49.3 (41.0-53.5) 42.0 (40.6-43.4) 0.333
Nuclear diameter 16.0 (15.5-17.8) 17.9 (17.3-18.5) 0.500
Atretic primary follicles
Follicle diameter 47.8 (32.7-52.4) 33.3 (30.1-38.8) 0.177
Nuclear diameter 13.1 (10.3-15.0) 11.6 (10.0-13.7) 0.329
Data are expressed as median (quartiles). Comparison between untreated and treated subjects are reported. Bold characters emphasize signiﬁcant P-values.
to the cytoplasm (Fig. 4B). All intact follicles of good morphology
(judged by DAPI staining) had a clear nuclear localization of FOXO3A,
suggestive of a dormant stage.
No increase in gammaH2AX expression in
ovarian tissues exposed to chemotherapy
WeevaluatedDNAdamage in our samples by gammaH2AX immunos-
taining. Only intact follicles were included in the analysis, as judged by
DAPI stained follicle morphology. Our staining showed no difference in
the number of gammaH2AX foci in oocyte nuclei from treated com-
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pared to untreated patients, suggesting no differences in DNA double-
strand breaks between the groups (P=0.416; Supplementary Fig. S2).
Ovarian tissue exposed to ﬁrst-line
chemotherapy produces less steroid
hormones during culture
For evaluation of follicle function, we quantiﬁed production of steroid
hormones during culture. Analysis of blank medium samples showed
no steroids present in basal medium. Cortisol, corticosterone and
dihydrotestosterone were undetectable in all samples. The average
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Figure 4 Exposure to chemotherapy before ovarian tissue cryopreservation does not increase activation of ovarian follicles. (A)
Box plots showing a signiﬁcantly smaller proportion of growing follicles in ovarian tissue of treated (n=14) and untreated (n=13) patients. For each
patient, the number of intact growing (intermediary and primary) follicles was divided by the total number of intact and atretic follicles (primordial,
intermediary and primary) ∗∗∗(P< 0.001). (B) Immunoﬂuorescence of ovarian tissue from a subset of treated (n=3) and untreated (n=5) patients
labeled with fork head box O3A (FOXO3A) antibody shows no differences between the two groups. FOXO3A is located in the nuclei of oocytes and
granulosa cells of both treated and untreated patients indicating non-activated follicles. Representative images of ovarian tissue sections are shown.
Table IV Steroid hormone concentrations in culture media of ovarian cortical strips from cancer patients untreated and
treated with chemotherapy before ovarian tissue cryopreservation (OTC) at Day 4 and at Day 7 of culture.
Hormone
(nM)
Day 4 Day 7
............................................................................ ....................................................................
Untreated
(n=13)
Treated (n=14) P-value Untreated
(n=13)
Treated (n=14) P-value
.....................................................................................................................................................................................
P4 13.0 (2.1-25.6) 0.8 (0.2-4.3) 0.035 24.6 (5.5-123.3) 3.7 (0.8-16.0) 0.073
17alphaOHP 0.1 (0.08-0.2) 0.04 (0.0-0.2) 0.3 0.3 (0.1-1.1) 0.2 (0.0-0.7) 0.27
A 0.6 (0.3-1.6) 0.2 (0.09-0.3) 0.021 1.6 (1.3-3.1) 0.5 (0.2-1.2) 0.016
T 0.1 (0.03-0.7) 0.01 (0.004-0.04) 0.002 0.6 (0.1-1.8) 0.05 (0.02-0.1) 0.013
E2 0.2 (0.0-1.5) 0.0 (0.0-0.1) 0.058 2.5 (0.2-8.5) 0.1 (0.0-0.5) 0.048
P4, progesterone; 17alphaOHP, 17 alpha hydroxyprogesterone; A, androstenedione; T, testosterone; E2, estradiol. P-value refers to the comparison of hormonal concentration in
culture media between untreated and treated ovarian cortical strips. Bold characters emphasize signiﬁcant P-values.
concentrations of estradiol, androstenedione, 17a-OH-progesterone,
dehydroepiandrosterone, testosterone and progesterone increased
over time in culture in both groups of patients, but were gener-
ally lower in treated compared to untreated patients (Table IV). In
treated patients compared to untreated ones, androstenedione and
testosterone concentrations were signiﬁcantly lower on Days 4 and
7, progesterone was signiﬁcantly lower on Day 4 and estradiol was
signiﬁcantly lower on Day 7 (Table IV). Steroid concentrations were
positively correlated with density of intact and growing follicles at both
time points (Supplementary Table SII).
First-line chemotherapy affects ovarian
stromal tissue
As a measure of ﬁbrosis in ovarian stroma, we carried out trichrome
assay that detects newly formed collagen-rich (ﬁbrotic) connective tis-
sue in blue (Fig. 5A). The stroma of patients exposed to chemotherapy
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showed signiﬁcantly larger areas of collagen with a greater intensity
compared to untreated patients (Fig. 5B). DNA fragmentation was
evaluated by TUNEL staining of ovarian tissue sections. All untreated
patients showed low levels of TUNEL staining in the ovarian stroma,
while treated patients showed TUNEL positive tissue areas to var-
ious degrees (Fig. 6A). Of the seven analyzed treated patients, ﬁve
showed clear increase in TUNEL signal while two remained similar
to untreated patients. When all patients were included in statistical
analysis, TUNEL signal showed only borderline increase in treated
compared to untreated patients (P=0.07, Fig. 6B). When the two
TUNEL-negative treated patient were removed from the analyses, the
difference became signiﬁcant (P=0.004).
Discussion
First-line chemotherapy is regarded as low risk in terms of gonado-
toxicity, and as such, does not represent an indication to perform
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Figure 5 Exposure to chemotherapy before ovarian tis-
sue cryopreservation increases collagen-rich stromal tissue
areas. (A) Representative images of trichrome assay performed
on ovarian tissue sections of treated (n=6) and untreated patients
(n=6). Newly formed collagen ﬁbers stain in blue. (B) Quantiﬁcation
of the blue component shows that the area of positive staining
and the signal intensity are increased in ovarian stromal tissue of
patients treated with chemotherapy before OTC. Dashed line indi-
cates reference value of control adult ovarian tissue (n=1) ∗(P< 0.05),
∗∗(P< 0.005).
OTC. This study provides, for the ﬁrst time, a comprehensive analysis
of the effects of ﬁrst-line chemotherapy on pre-antral follicles and
on the stromal compartment in girls and young women 24 years
of age and below. We found a higher number of atretic follicles in
ovaries exposed to ﬁrst-line chemotherapy before OTC compared
to those who were not. In addition, we found that treated patients
had signiﬁcantly smaller intact follicles in the earliest stages of devel-
opment (primordial and intermediary). The diameters of untreated
follicles and oocyte nuclei were in line with the previously reported
normative values (Westergaard et al., 2007), whereas the diameters
in the treated group were substantially smaller. This might suggest
that even follicles that escape atresia after chemotherapy exposure
exhibit signiﬁcant morphological alterations that could have functional
consequences. In addition to altered morphology, the density of intact
primary follicles was signiﬁcantly reduced in the treated group, possibly
indicating a lower in vivo developmental potential of the follicles. These
data support our previous in vitro culture study, where we reported
an impairment of the developmental potential of ovarian follicles in
samples collected after chemotherapy (Asadi Azarbaijani et al., 2015).
We observed that both the cumulative doses of anthracyclines and
alkylating agents as well as the patient’s age inﬂuence the size of
intact intermediary follicles and their ability to progress toward the
primary stage, with anthracyclines showing an independent effect. In
clinical settings, anthracyclines are classiﬁed as safe in terms of risk
of ovarian insufficiency. McLaughlin et al. (2017) reported that non-
growing follicle density was not depleted but even increased in adult
women after exposure to anthracyclines as part of the adriamycin,
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bleomycin, vinblastine and dacarbazine protocol for Hodgkin lym-
phoma. However, our observation of an adverse effect of anthracy-
clines in tissues cryopreserved for fertility preservation highlights that
other ﬁrst-line chemotherapeutics than those associated with long-
term ovarian toxicity may also have an impact on follicle quality, at least
in young patients.
Follicle activation
The ‘burn-out’ mechanism has been proposed as a potential mech-
anism of chemotherapy-induced infertility in mice (Kalich-Philosoph
et al., 2013; Roness et al., 2016), bovine (Gavish et al., 2015) and
human ovary (Lande et al., 2017). Nuclear localization of FOXO3A
marks the dormant state of follicles (Li et al., 2010). All intact pri-
mordial follicles in our samples expressed FOXO3A in the nucleus. In
addition, we observed a reduced ratio of growing to total follicles in
treated versus untreated patients, leading us to reject the hypothesis
of an increased activation of follicles in treated patients. It should be
noted that the time since last treatment varied from 7 to 55 days,
which could reduce chances of detecting possible temporary follicle
activation.
DNA damage in follicles
We observed a similar amount of gammaH2AX foci in oocyte nuclei
between treated and untreated patients. GammaH2AX is one of the
ﬁrst molecules recruited at DNA damage sites during the process
of DNA repair. Mouse studies have shown that phosphorylation of
H2AX happens in the oocyte nucleus around 10 min after DNA
damage (Rogakou et al., 1998; Ji et al., 2017), reaching a peak after
24 h (Gonﬂoni et al., 2009; Petrillo et al., 2011; Rossi et al., 2017).
Assuming that H2AX follows the same kinetics in human ovaries, we
might have failed to detect higher levels, as chemotherapy has been
administered 8–55 days beforeOTC in analyzed treated cases. Alterna-
tively, gammaH2AX might not be a suitable marker for cell death after
chemotherapy, which could instead be mediated by oxidative stress or
indirectly by stromal damage (Tsai-Turton et al., 2007).
Follicle function
Analysis of media from ovarian cultures showed production of
both theca and granulosa cell-speciﬁc hormones, with increasing
concentrations over time in culture and levels comparable to those
produced by cultured ovaries of adult patients (Hao et al., 2018).
According to literature, theca and granulosa cells express steroidogenic
enzymes from the secondary follicle stage (Andersen and Ezcurra,
2014). In our samples, the number of secondary follicles was very low
and steroid production was positively associated with the density of
intact intermediary and primary follicles. Very little is known about
the steroidogenic activity of pre-pubertal ovaries. However, fetal
ovaries are capable of producing estradiol already from the second
trimester, i.e. when primordial follicle formation occurs and pre-
granulosa cells appear (Fowler et al., 2011), suggesting that the steroids
detected in our samples could be secreted by pre-antral follicles.
Alternatively, somatic cells might acquire steroidogenic potential
after exposure to the in vitro environment, as previously suggested
(Oktem and Oktay, 2007). If this is the case, the overall lower
steroid concentration in ovarian tissue from treated patients could
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Figure 6 DNA fragmentation in ovarian stromal cells is inﬂuenced by ﬁrst-line chemotherapy. (A) Representative images showing
DNA damage in nuclei of stromal cells of untreated and treated patients. As positive control (PC), the tissue section was pre-treated with DNase I.
As negative control (NC), no detection enzyme was used. (B) Quantiﬁcation of TUNEL signal in stromal cell nuclei relative to the total nuclear area of
the stained tissue sections of untreated (n=6) and treated patients (n=7).
also be caused by the chemotherapy-induced stromal damage that we
observed.
Ovarian stromal cells
Analysis of cortical stroma revealed a signiﬁcant increase in ﬁbrotic area
and an increase in DNA damage in treated compared to untreated
patients. This ﬁnding is supported by other reports showing cortical
ﬁbrosis (Meirow et al., 2007) and stromal apoptosis (Fabbri et al.,
2016) in ovarian tissue upon chemotherapy treatment. If stromal cells
play a role in steroid production (as suggested by our steroid data),
then ﬁbrotic stroma might affect the quality of non-growing as well as
early growing follicle.
Limitations
Our study has limitations. The study population was heterogeneous
in terms of age and treatment exposures. Younger age might have
contributed to the higher follicle atresia in the treated group. Further-
more, the impact of speciﬁc treatments could not be assessed. The
limited tissue availability did not allow us to perform all the analyses in
all patients and subsets had to be used, lowering the statistical power.
In summary, we demonstrated that exposure to ﬁrst-line cancer
treatment negatively impacts follicle number, follicle morphology,
steroid secretion in culture and ovarian stromal compartment.
Furthermore, we were able to show that atretic death in primordial
follicles rather than ovarian ‘burn-out’ through follicle activation might
be the dominant mechanism of action of ovarian failure following
chemotherapy, as has also been suggested by others (Kerr et al., 2012;
Bedoschi et al., 2016; Nguyen et al., 2018; Winship et al., 2018).
We observed a signiﬁcant correlation between the density of atretic
follicles and the cumulative exposure to alkylating agents and anthra-
cyclines, which are widely used as ﬁrst-line therapy in many pediatric
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solid cancers and hematological malignancies. The combined treatment
with both drug types in the majority of the treated patients prevented
identiﬁcation of any drug-speciﬁc effects. Our observations suggest
that OTC should be performed earlier, before the initiation of any
chemotherapy, in order to prevent adverse effects on follicles and
stroma. Follow-up investigations should focus on chemotherapy agent-
speciﬁc effects on human follicles. In addition, assessing treatment
effects on pre-pubertal primordial follicles as compared to adult pri-
mordial follicles should be considered.
Supplementary data
Supplementary data are available at Human Reproduction online.
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